Compare Dollar Tree, Inc. (DLTR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Dollar Tree, Inc. trades at $126.19 (market cap $23.94B), while Recursion Pharmaceuticals Inc trades at $3.4 (market cap $1.78B). The key difference: Dollar Tree, Inc. is far larger — about 13.4× Recursion Pharmaceuticals Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| DLTR | RXRX | |
|---|---|---|
Market Cap | $23.94B | $1.78B |
Sector | Health | Health |
52-Week High | $141.21 | $6.79 |
52-Week Low | $85.04 | $2.84 |
Enterprise Value | $30.52B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $126.38, up 1.18% today, with a bullish technical signal and strong recent earnings beats. The company's fundamentals show a net loss in 2025 but improving cash flow and a $2.5 billion share repurchase authorization signal confidence. Analyst consensus is a Buy with a $131 price target, though valuation ratios like P/E of 20.29 and P/B of 6.93 reflect moderate pricing.
The outlook is positive due to earnings momentum and cost controls, but risks include traffic softness and tariff pressures. Upside potential exists if margin gains and multi-price strategy sustain growth, yet investors must weigh high debt and competitive headwinds against cash flow strength and institutional support.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
